Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
2023年11月3日 - 5:05AM
ビジネスワイヤ(英語)
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for rare endocrine disorders with significant unmet
medical need, today announced that company management will
participate in the Jefferies London Healthcare Conference on
November 14-16, 2023.
Archived webcasts from investor conferences are available on the
events section of the company’s investor relations website.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for rare
endocrine disorders with significant unmet medical need. Spruce is
initially developing its wholly-owned product candidate,
tildacerfont, as the potential first non-steroidal therapy for
patients suffering from classic congenital adrenal hyperplasia
(CAH). Spruce is also developing tildacerfont for women suffering
from polycystic ovary syndrome (PCOS). To learn more, visit
www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn,
Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102088017/en/
Media Contact Will Zasadny Evoke Canale (619) 961-8848
will.zasadny@evokegroup.com media@sprucebio.com
Investors Samir Gharib President and CFO Spruce
Biosciences investors@sprucebio.com
Spruce Biosciences (NASDAQ:SPRB)
過去 株価チャート
から 4 2024 まで 5 2024
Spruce Biosciences (NASDAQ:SPRB)
過去 株価チャート
から 5 2023 まで 5 2024